Vessix Vascular, a developer of percutaneous radiofrequency (RF) balloon catheter technology, is set to present its new V2 Renal Denervation system preclinical data.

The V2 Renal Denervation System features an over the wire balloon catheter with electrodes mounted on the exterior of the balloon and is connected to a proprietary low power bipolar RF generator.

After inflation in the artery, the balloon catheter’s RF energy is activated for 30 seconds resulting in the disruption of the renal nerves located in the adventitia that surround the renal artery, thus treating hypertension.

Interventional cardiology luminary James Margolis said the data provides significant angiographic and histological evidence of safety and also effectiveness in reducing kidney norepinephrine levels – a surrogate for reduction of blood pressure in humans.

" We look forward to see the results of the upcoming multi-center international clinical study set to begin in Europe later this month," Margolis said.

Vessix sais it will present its V2 Renal system preclinical results on 18 February 2012 at the TRenD Workshop 2012 in Frankfurt, Germany.